Contact
Please use this form to send email to PR contact of this press release:
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
TO:
Please use this form to send email to PR contact of this press release:
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
TO: